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Summary The variations in uptake of 3H-vincristine sulphate, given as a bolus i.v. injection, by a
transplantable murine tumour during a realistic course of fractionated daily y-radiation of 25 x 2.0Gy have
been investigated. Maximum levels of 3H in the tumours are found when the tracer is injected 4h after
irradiation and the tumours are dissected out 1 h after injection. During the course of daily irradiation the
pattern of uptake varies considerably but reproducibly. There are peaks of uptake after 7, 13 and 22 fractions
of 2.0Gy when the amount of 3H in the tumours is as much as three times that found in non-irradiated
tumours. After 17-18 fractions, however, the tumour content of 3H is lower than that of non-irradiated
tumours. The wave-like pattern of uptake could be due either to capillary occlusion brought about by
radiation induced cellular swelling and oedema followed by re-opening of the capillaries during periods of
decreased cellularity, or to some mechanism of recovery from radiation damage during the week-end rest
period.
The substantial number of recent publications on the subject
indicate that the use of combined modality treatment (CMT;
Howes, 1988) is increasing. In CMT, chemotherapeutic
agents are given either before, during or after a course of
fractionated radiotherapy.
The choice of the type of chemotherapeutic agent(s) to be
administered and the timing of its administration are based
or radiobiological principles as well as consideration of
normal tissue damage and the general state of health of the
patient (Steel, 1988; Brown, 1979; Tubiana et al., 1985).
Thus when oncologists speak of 'radiation-drug interaction'
they mean the enhancement of, or protection from, the
effects of radiation on normal and/or malignant tissues
(Steel, 1979). Although these considerations are logical and
valid there is one effect of radiation which is never taken
into account but which may have significant implications for
the success or failure of CMT: the effects of radiation on
vascular integrity.
It is by now fairly well established that radiation has
profound effects on vascular function in the irradiated tissue,
resulting in alterations in blood flow (Zanelli & Lucas,
1976), in the structure of the capillary endothelium (Eddy,
1980) and in the extravasation of plasma macromolecules
(Krishnan et al., 1988). Furthermore, there are indications
that the vascular effects of radiation are not random but
systematic, i.e. are functions of the radiation dose and the
time after radiation, and that the sequence of events is
different in normal and malignant tissues (Zanelli & Lucas,
1976). Although the effects of radiation on cell membranes
are less well understood they appear to involve loss of
surface lipids (Bacq & Alexander, 1966) leading to loss of
integrity and altered permeability to a variety of chemical
entities.
One further point of importance in the present context
concerns the shape of the cell survival curves following
chemotherapy. Although much is known about cell survival
curves after irradiation, we know much less about cell
survival after chemotherapy. The available evidence (Masters
& Hepburn, 1986) suggests that biphasic or exponential cell
survival curves with very different slopes can be obtained
depending on the choice of drug and the cell line under
investigation. A judicious choice of drug/cell line
combination can result in exponential cell survival curves
with steep slopes. In this case doubling the amount of drug
reaching the target cells can lead to much more than double
the effect on the cell population. On the other hand, if the
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amount of drug reaching the cellular milieu is reduced (e.g.
due to the physiological effects of radiation on the
vasculature) then the effects of chemotherapy may be
substantially reduced.
There are at present no data at all on the effects of
radiation on tumour levels of chemotherapeutic agents
during fractionated radiotherapy. Plasma levels of drugs are
not much help since it has been shown that they may bear
little or no relationship to tumour levels (Donelli et al., 1984;
Anderson et al., 1970), yet most reports on new regimes of
combined radiotherapy-chemotherapy confine themselves to
reporting plasma levels and urinary excretion of the drugs.
In what follows, a systematic approach has been devised to
assess the quantity of a widely (and commercially available
in radioactively labelled form) used chemotherapeutic agent
(vincristine) which accumulates in an experimental mouse
tumour model throughout a realistic course of fractionated
radiotherapy.
Materials and methods
Mice and tumour
Eight- to twelve-week-old male CBA/He mice were used
throughout. They were kept under standard animal house
conditions; controlled light cycles, and allowed access to
food and water ad libitum.
The tumour was a carcinoma, designated as carcinoma
NT or neck tumour, which arose spontaneously in this strain
of mice some 20 years ago and has been serially passaged
ever since. This tumour, which has been fully described by
Hewitt et al. (1976), has now been transplanted into more
than 10,000 mice. There has never been a single 'no take' or
spontaneous regression.
For transplanting, tumour tissue was minced with fine,
sterilised scissors in a sterile Petri dish. The mince was then
transferred to a sterile tube, shaken with 5-10ml of saline
and allowed to stand for a few minutes until all the coarse
debris had settled. After a quick cell count in a haemo-
cytometer chamber, the volume of supernatant was adjusted
to contain a concentration of 15-20 x 103 cells in an injection
volume of 0.05ml and this volume was injected intra-
dermally in the previously shaven flank of recipient mice
using a 1 ml syringe and 25 G needle.
During all experiments the tumours were measured with
calipers in three perpendicular dimensions. A mean
geometrical diameter was calculated as d=(abc)"3.
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Irradiation
The available source was a 3kCi cobalt-60 small animal
irradiation facility. The heavy field-defining cone of the
irradiator was used to protect the mice's bodies. The dose
rate at the site of the tumour and the body was measured
with an ionization chamber and lithium fluoride thermo-
luminescence dosimetry. The dose rate at the beginning of
the series of experiments was 10.2cGymin-1 at the tumour
site and 0.006cGy min- at the centre of a mouse's body.
During the course of the experiments the dose-rate was
corrected weekly for the decay of the source. The irradiation
chamber was kept at about 30°C during irradiation to
prevent hypothermia in the mice which were sedated with
mild doses of Hypnorm i.p. (Jansen Pharmaceutical Ltd,
Oxford, UK).
3H-vincristine
Tritiated vincristine sulphate was bought from Amersham
International (Amersham, Bucks, UK, code TRK 478, sp. act
74-370 GBqmol-1). It is supplied in 0.2ml of 0.01 N
sulphuric acid and for injection it was diluted with saline to
an activity content of about 110kBq in 0.1ml and this
volume was injected i.v. in a lateral tail vein of the mice. The
amount of vincristine injected varied between 0.18 and
2.3pg.
Experimental protocols
The project reported herein involved six separate but
interdependent experiments. In general, a larger number of
mice than that required for any given experiment were
inoculated intradermally with 15-20 x 103 tumour cells. Out
of these the required number of animals was selected on the
basis of similar tumour size and true intradermal site.
Irradiation was always started when the tumours were
5-6mm in average diameter. For the sake of clarity each
experiment will be described individually.
Experiment I One hundred tumour bearing mice were
started on daily treatments with 2Gy of radiation, five days
per week for five weeks, beginning on a Monday. Irradiation
was always carried out between 8.30 and 9.30 in the
morning. After each fraction, four mice were withdrawn
from the experiment, injected with 3H-vincristine i.v. 1 h
after the midpoint of the radiation treatment and killed
(stunning and decapitation) 1 h after the injection of the
tracer. The tumour, a blood sample (from the severed neck
vessels) and various organs (liver, spleen, kidneys, lungs)
were removed and accurately weighed. For this and all
subsequent experiments the 3H content of the tissues was
measured by burning them in a sample oxidiser (Packard
Sample Oxydizer, model B306, Packard Instruments,
Caversham, UK) followed by counting in an LKB Wallac
1280 gamma counter (Pharmacia Ltd, Milton Keynes, UK)
together with appropriate standards (aliquots of the injected
dose burned as for the tissues).
Experiment 2 The tumours of 24 mice 'were given 7 x 2 Gy
daily irradiation. The mice were then injected in groups of
four with 3H-vincristine at various times later (0.5-24h) and
killed 1 h after injection.
Experiment 3 A group of 24 mice had their tumours
irradiated to 7 x 2Gy. The mice were injected with the tracer
4h after the last fraction and killed in groups of four at
various times (0.5-24h) after injection.
Experiment 4 Since the tumours continue to grow during a
protracted regime of fractionated irradiation, the effect of
tumour size on the uptake of 3H-vincristine per unit weight
of tumour tissue had to be determined. In experiment 4
therefore a large group of mice was inoculated intradermally
with the tumour cells and their tumours measured daily.
During the growth of the tumours (- 4 weeks) groups of
four mice with tumours of similar size were injected with the
tracer, killed 1 h later and the 3H content per unit weight of
tumour determined as described above. This was continued
until tumours of a mean diameter of - 12mm were obtained
and the experiment was then stopped.
Experiment 5 Eight groups of four mice with non-irradiated
tumours of similar size (d=5.8+0.6mm) were injected with
3H-vincristine i.v. and killed at various times (0.5-24h) after
injection. The tumour and blood content of 3H was
determined as usual.
Experiment 6 This was the same as experiment 1 (daily
irradiations of 2Gy, five days per week for 5 weeks) except
that after each fraction a group of four mice was withdrawn
and injected 4h after irradiation (lh in experiment 1) and
killed 1 h after injection (as for experiment 1). In this
experiment only the tumour and blood were collected.
Results
The results of experiment 1 are shown in Figure 1. There are
substantial variations in the uptake of 3H per unit weight of
tumour throughout the course of fractionated radiation.
After 7 x 2Gy the amount of tracer in the tumour is more
than twice that found at the beginning of the experiment. On
the other hand, after 15-18 fractions of 2Gy the uptake falls
to about one-third of that on day 1. In this and all
subsequent figures the bars represent the standard error of
the means.
The troughs at 9 and 17 days could be due to a reduction
in uptake in larger tumours as shown in Figure 2, coupled
with recovery of the vasculature during the week-end rest
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Figure 1 Experiment 1: 3H content per gram of tumour as
percentage of the injected dose after each of 25 daily fractions of
2Gy 60Co irradiation to the tumour. The mice were injected with
3H-vincristine i.v. 1 h after irradiation and killed 1 h after
injection. The vertical bars are the standard errors of the means
(n=4).
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Figure 2 Effect of tumour size (d=(abc)"13) on the uptake of
3H. The mice were killed and the tumours excised one hour after
the injection (i.v.) of 3H-vincristine.
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period from radiation damage. The peaks appear to be real
and suggest increased extravasation of drug through
radiation damaged capillary endothelium.
Figure 3 shows the percentage of injected dose per gram
of liver and lung throughout the course of fractionated
tumour irradiation in experiment 1. The uptake in these
organs is fairly constant. The growth pattern of the NT
tumour with and without irradiation is shown in Figure 4.
This tumour is fairly radioresistant and continues to grow, at
a reduced rate, during the radiation treatment (the data
points are for a group of mice which had undergone the full
5 week treatment during experiment 1). There is little
evidence of tumour control even after 25 fractions of 2Gy.
Figure 5 shows that in non-irradiated tumours the uptake
of 3H per unit weight remains reasonably constant up to
24h after injection (experiment 5). The amount of tracer in
the tumour tissue stays below the concentration in the blood.
Figures 6 and 7 show the pattern of uptake of 3H in
tumours given seven fractions of 2Gy (the peak of uptake in
experiment 1, Figure 1) with time after irradiation (experi-
ment 2, Figure 6) and time after injection (experiment 3,
Figure 7). They show that the maximum uptake in tumours
is achieved if the mice are injected four hours after
irradiation and killed one hour after injection. Furthermore,
the amount of tracer in the tumours after 7 x 2Gy of
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Figure 3 3H content per gram of liver (filled cir
(open circles) tissue during a fractionated course
60Co irradiation delivered to the tumour only. Th
are the standard errors of the means (n=4).
Figure 5 3H content per gram of tumour and blood of non-
irradiated mice as a function of time after i.v. injection of 3H-
vincristine. The vertical bars are the standard errors of the means
(n=4). Open circles, blood; filled circles, tumour.
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Figure 4 Growth of the carcinoma-NT. Open
irradiated controls; filled circles, tumours give
6'Co-irradiation.
Figure 6 3H content per gram of tissue in mice given 7 x 2Gy
daily 60Co irradiation to the tumour, injected with 3H-vincristine
i. at various times after the last fraction and killed 1 h after
injection. Filled circles, tumour; open circles, blood. The vertical
b;ars arc the standard errors of the means (n=4).
radiation is greater than that in non-irradiated tumours
(Figure 5) and is above the blood concentration.
Figure 8 shows the results of experiment 6 in which the
experimental conditions have been optimised on the basis of
the results of experiments 2 and 3, i.e. the mice were injected
20 25 4h after a given fraction of radiation and killed one hour
after injection. The rhythmic pattern of tracer uptake is
circles, non- similar to that of experiment 1 (Figure 1) but the absolute
n 2Gy daily values are higher, as would be expected from the results
shown in Figures 6 and 7.
6-
0)
:, 5- cn
%._
o 4-
0)
a. 3-
en 0)
-a 2-
.-_
C'
_o 1-
24
u
15-
E 10-
5-
I
T
r] -- Is t -j
0- v - F-
i
I I -1111,
u
lli..
r I
.-I
vRADIATION AND VINCRISTINE TUMOUR UPTAKE 313
0
C)
a)
0.
a)
Co
0
.V-
I-0
Hours post-injection
Figure 7 3H content per gram of blood and tumour in mice
given 7x2Gy daily 60Co irradiation to the tumour, injected i.v.
with 3H-vincristine 1 h after the last fraction and killed at
various times after injection. Filled circles, tumour; open circles,
blood. The vertical bars are the standard errors of the means
(n =4).
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Figure
8 Experiment 6: 3H content per gram of tumour as
percentage
of the injected dose after each of 25 daily fractions of
2 Gy 60Co irradiation to the tumour. The mice were injected with
3H-vincristine i.v.
4h after irradiation and kilted 1h after
injection. The vertical bars are the standard errors of the means
(n 4).
Discussion
Combined radiotherapy and chemotherapy in the treatment
of human cancer is slowlygaining favour. Early in the use of
CMT it became apparent that radiation and drugs could
interact in several ways and attempts were made to
rationalise the semantics of such interactions (Steel, 1979), to
study their mechanisms (Wheeler & Kaufman, 1980; van der
Maase, 1984; Joiner et al., 1984) and to propose more
realistic models for the study of such interactions in humans
(Rubin et al., 1988).
It has recently become evident that the time sequence of
administration of the two modalities plays an important part
in determining the observed results (Twentyman et al., 1979;
Begg et al., 1979; Collis & Steel, 1983; Pearson & Steel,
1984; Fu et al., 1985, 1988; Lelieveld et al., 1985). Although
in most cases involving experimental mouse tumours single
doses, continuous low dose-rate or a small number of large
fractions of radiation were used, the results in general tend
to show that there is greater enhancement of the radiation
effects when the drugs are given shortly before or shortly
after the radiation. Depending on the effects observed the
results have been variously interpreted as due to factors such
as repopulation, movement of cells to a phase more sensitive
to the drug or inhibition of recovery from radiation damage.
Although these factors are very likely to play a role in the
observed results it is difficult to draw any firm conclusions
unless the actual quantity of drug reaching the target cells is
known with reasonable accuracy: lack of potentiation may
simply mean' that only a small percentage of the drug
reaches or is prevented from reaching the tumour tissues.
That this can happen during a realistic course of fractionated
radiation has been shown in this communication and has
been recognised as a possible source of error in CMT by
other authors (Looney et al., 1985; Tannock & Sindelar,
1988).
As for possible explanations of the results reported in this
paper, the effects of radiation on the tumour vasculature
must be the prime candidate. It has been known for a long
time that radiation has severe effects on blood flow and
extravasation of macromolecules (Zanelli & Lucas, 1976;
Song & Levitt, 1970) and has recently been confirmed by
Krishnan et al., (1988), who showed that there is an
immediate increase in extravasation of albumin after doses
of radiation as low as 2Gy.
The sinusoidal character of the uptake curves (Figures 1
and 8) is a hitherto unexplained but reproducible
phenomenon. Zanelli (1977) has shown that the blood pulse
in irradiated human skin during and after a course of
fractionated radiotherapy shows similar variations in time.
As far back as 1928, Mottram showed that after irradiation
tumour cells swell up and tend to occlude the capillaries. It
is conceivable that during fractionated radiation periods of
cellular swelling and oedema alternate with periods of
decreased cellularity and reopening of the blood vessels. The
fact that the peaks of uptake (Figures 1 and 8) seem to
coincide with the days following the week-end rest also
suggests that the 'wave like' effects seen could be due to
some mechanism of recovery from radiation damage. This
opens up interesting possibilities in view of current thoughts
of continuing radiotherapy over week-ends.
Whether the results of the present investigation apply to
all drugs and all tumours, especially human tumours, is not
known, and neither is the effect of different fractionation
regimes. On the basis of the above discussion one would
expect all drugs to behave at least qualitatively in a similar
manner. However, different tumours and fractionation
schedules may show different temporal effects.
As stated in the Introduction the available evidence
suggests that the effects of radiation on malignant and
normal tissues with respect to extravasation are qualitatively
similar but displaced in time. If one has to calculate
parameters such as 'therapeutic gain' from CMT experiments
it is essential that these temporal differences be investigated
during realistic regimes of fractionated radiation, i.e. with
experiments of the type reported above on tumours and
normal tissues.
Since in clinical practice concurrent radiotherapy and
chemotherapy are not only being seriously considered, but
actually practised, the above questions are critical. Animal
experiments are obviously the quickest way of obtaining
answers, but the question still remains of how closely animal
models mimic the human situation. The type of experiments
described in this paper can be carried out in some types of
human cancer where at least one extra biopsy can be taken
without undue discomfort to the patients. Alternatively, with
modern non-invasive methods of detection (e.g. positron
emission tomography) it may be possible to quantitate tissue
uptake of therapeutic agents labelled with positron-emitting
radionuclides.
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